---
document_datetime: 2025-12-02 05:33:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mvabea.html
document_name: mvabea.html
version: success
processing_time: 0.1094654
conversion_datetime: 2025-12-27 21:11:20.794832
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mvabea

[RSS](/en/individual-human-medicine.xml/67327)

##### Authorised

This medicine is authorised for use in the European Union

Ebola vaccine (MVA-BN-Filo [recombinant]) Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mvabea](#news-on)
- [More information on Mvabea](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Mvabea is a vaccine to protect adults and children aged one year and older against Ebola virus disease caused by *Zaire ebolavirus* . It is used with another Ebola vaccine called Zabdeno as part of a vaccine regimen.

Mvabea contains a virus known as Vaccinia Ankara Bavarian Nordic which has been modified to produce 4 proteins from *Zaire ebolavirus* and three other viruses of the same group ( *filoviridae* ). The modified vaccinia Ankara Bavarian Nordic virus itself has no effect on humans. Mvabea only contains parts of the viruses and cannot cause Ebola virus disease.

Expand section

Collapse section

## How is Mvabea used?

Mvabea can only be obtained with a prescription and is given by a trained healthcare worker. It is given as a single injection about 8 weeks after an injection of Zabdeno. People who are at imminent risk of infection with Ebola virus and have received the Zabdeno and Mvabea injections more than 4 months earlier can receive a booster dose of Zabdeno.

Injections are given into the muscle around the shoulder (the deltoid) or a muscle of the thigh.

For more information about using Mvabea, see the package leaflet or contact your doctor or pharmacist.

## How does Mvabea work?

The active substance in Mvabea, when injected in the body, produces 4 viral proteins characteristic of *filoviridae* , the group of viruses that includes *Zaire ebolavirus* . When a person receives the vaccine regimen, the viral proteins trigger an immune response. If later on the person comes into contact with *Zaire ebolavirus* , the immune system recognises the viral proteins and is prepared to attack the virus, so protecting the person from the disease caused by Ebola virus.

## What benefits of Mvabea have been shown in studies?

Five main studies showed that Mvabea, when used with Zabdeno, can trigger the production of antibodies capable of providing protection against *Zaire ebolavirus* . The studies involved a total of 3,585 adults and children. Based on animal studies with a fully lethal dose of the virus, the antibody level generated in humans following vaccination with Zabdeno and Mvabea would be expected to lead to around 53% survival if infected with a fully lethal dose. However, the method used in the animal studies results in more severe infection than natural infection in humans. Although the vaccine regimen can provide protection against Ebola virus disease, the level and duration of protection are not yet known and the company will provide further data.

## What are the risks associated with Mvabea?

The most common side effects in adults with Mvabea (which may affect more than 1 in 10 people) are pain, warmth and swelling at the injection site, tiredness, muscle pain and joint pain.

In children and adolescents aged 1 to 17 years, the most common side effects (which may affect more than 1 in 10 people) are pain at the injection site and tiredness.

For the full list of side effects and restrictions of Mvabea, see the package leaflet.

## Why is Mvabea authorised in the EU?

Mvabea, used with Zabdeno as part of a 2-dose vaccine regimen, triggers an immune response that can provide protection against Ebola virus disease. Although the level and duration of protection against the virus have not yet been determined, the European Medicines Agency considered that the vaccine's benefits could be of great importance to help control an outbreak and prevent death. Regarding safety, most side effects are mild to moderate in severity and of short duration. The Agency therefore decided that Mvabea's benefits are greater than its risks and it can be authorised for use in the EU.

Mvabea has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Mvabea for scientific and ethical reasons. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Mvabea?

Since Mvabea has been authorised under exceptional circumstances, the company that markets Mvabea will provide an update on the collection of data on the effectiveness of the vaccine regimen in the intended population on a yearly basis.

## What measures are being taken to ensure the safe and effective use of Mvabea?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mvabea have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mvabea are continuously monitored. Side effects reported with Mvabea are carefully evaluated and any necessary action taken to protect patients.

## Other information about Mvabea

Mvabea received a marketing authorisation under exceptional circumstances valid throughout the EU on 01 July 2020.

Mvabea : EPAR - Medicine overview

Reference Number: EMA/298993/2020

English (EN) (137.22 KB - PDF)

**First published:** 23/07/2020

[View](/en/documents/overview/mvabea-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-547)

български (BG) (160.05 KB - PDF)

**First published:**

23/07/2020

[View](/bg/documents/overview/mvabea-epar-medicine-overview_bg.pdf)

español (ES) (140.83 KB - PDF)

**First published:**

23/07/2020

[View](/es/documents/overview/mvabea-epar-medicine-overview_es.pdf)

čeština (CS) (146.68 KB - PDF)

**First published:**

23/07/2020

[View](/cs/documents/overview/mvabea-epar-medicine-overview_cs.pdf)

dansk (DA) (124.18 KB - PDF)

**First published:**

23/07/2020

[View](/da/documents/overview/mvabea-epar-medicine-overview_da.pdf)

Deutsch (DE) (127.96 KB - PDF)

**First published:**

23/07/2020

[View](/de/documents/overview/mvabea-epar-medicine-overview_de.pdf)

eesti keel (ET) (121.63 KB - PDF)

**First published:**

23/07/2020

[View](/et/documents/overview/mvabea-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.91 KB - PDF)

**First published:**

23/07/2020

[View](/el/documents/overview/mvabea-epar-medicine-overview_el.pdf)

français (FR) (127 KB - PDF)

**First published:**

23/07/2020

[View](/fr/documents/overview/mvabea-epar-medicine-overview_fr.pdf)

hrvatski (HR) (145.89 KB - PDF)

**First published:**

23/07/2020

[View](/hr/documents/overview/mvabea-epar-medicine-overview_hr.pdf)

italiano (IT) (124.79 KB - PDF)

**First published:**

23/07/2020

[View](/it/documents/overview/mvabea-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (154.64 KB - PDF)

**First published:**

23/07/2020

[View](/lv/documents/overview/mvabea-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (156.43 KB - PDF)

**First published:**

23/07/2020

[View](/lt/documents/overview/mvabea-epar-medicine-overview_lt.pdf)

magyar (HU) (147.33 KB - PDF)

**First published:**

23/07/2020

[View](/hu/documents/overview/mvabea-epar-medicine-overview_hu.pdf)

Malti (MT) (148.6 KB - PDF)

**First published:**

23/07/2020

[View](/mt/documents/overview/mvabea-epar-medicine-overview_mt.pdf)

Nederlands (NL) (125.16 KB - PDF)

**First published:**

23/07/2020

[View](/nl/documents/overview/mvabea-epar-medicine-overview_nl.pdf)

polski (PL) (150.77 KB - PDF)

**First published:**

23/07/2020

[View](/pl/documents/overview/mvabea-epar-medicine-overview_pl.pdf)

português (PT) (126.44 KB - PDF)

**First published:**

23/07/2020

[View](/pt/documents/overview/mvabea-epar-medicine-overview_pt.pdf)

română (RO) (146.42 KB - PDF)

**First published:**

23/07/2020

[View](/ro/documents/overview/mvabea-epar-medicine-overview_ro.pdf)

slovenčina (SK) (148.66 KB - PDF)

**First published:**

23/07/2020

[View](/sk/documents/overview/mvabea-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145.45 KB - PDF)

**First published:**

23/07/2020

[View](/sl/documents/overview/mvabea-epar-medicine-overview_sl.pdf)

Suomi (FI) (122.13 KB - PDF)

**First published:**

23/07/2020

[View](/fi/documents/overview/mvabea-epar-medicine-overview_fi.pdf)

svenska (SV) (123.01 KB - PDF)

**First published:**

23/07/2020

[View](/sv/documents/overview/mvabea-epar-medicine-overview_sv.pdf)

Mvabea : EPAR - Risk management plan

English (EN) (662.15 KB - PDF)

**First published:** 23/07/2020

**Last updated:** 25/03/2025

[View](/en/documents/rmp/mvabea-epar-risk-management-plan_en.pdf)

## Product information

Mvabea : EPAR - Product information

English (EN) (375.04 KB - PDF)

**First published:** 23/07/2020

**Last updated:** 14/05/2025

[View](/en/documents/product-information/mvabea-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-285)

български (BG) (391.44 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/bg/documents/product-information/mvabea-epar-product-information_bg.pdf)

español (ES) (417.44 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/es/documents/product-information/mvabea-epar-product-information_es.pdf)

čeština (CS) (540.48 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/cs/documents/product-information/mvabea-epar-product-information_cs.pdf)

dansk (DA) (495.53 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/da/documents/product-information/mvabea-epar-product-information_da.pdf)

Deutsch (DE) (671.41 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/de/documents/product-information/mvabea-epar-product-information_de.pdf)

eesti keel (ET) (516.45 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/et/documents/product-information/mvabea-epar-product-information_et.pdf)

ελληνικά (EL) (370.91 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/el/documents/product-information/mvabea-epar-product-information_el.pdf)

français (FR) (329.64 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/fr/documents/product-information/mvabea-epar-product-information_fr.pdf)

hrvatski (HR) (356.83 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/hr/documents/product-information/mvabea-epar-product-information_hr.pdf)

íslenska (IS) (516.72 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/is/documents/product-information/mvabea-epar-product-information_is.pdf)

italiano (IT) (361.4 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/it/documents/product-information/mvabea-epar-product-information_it.pdf)

latviešu valoda (LV) (439.35 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/lv/documents/product-information/mvabea-epar-product-information_lv.pdf)

lietuvių kalba (LT) (466.09 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/lt/documents/product-information/mvabea-epar-product-information_lt.pdf)

magyar (HU) (344.66 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/hu/documents/product-information/mvabea-epar-product-information_hu.pdf)

Malti (MT) (429.2 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/mt/documents/product-information/mvabea-epar-product-information_mt.pdf)

Nederlands (NL) (458.9 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/nl/documents/product-information/mvabea-epar-product-information_nl.pdf)

norsk (NO) (408.43 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/no/documents/product-information/mvabea-epar-product-information_no.pdf)

polski (PL) (563.88 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/pl/documents/product-information/mvabea-epar-product-information_pl.pdf)

português (PT) (422.56 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/pt/documents/product-information/mvabea-epar-product-information_pt.pdf)

română (RO) (606.03 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/ro/documents/product-information/mvabea-epar-product-information_ro.pdf)

slovenčina (SK) (659.94 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/sk/documents/product-information/mvabea-epar-product-information_sk.pdf)

slovenščina (SL) (745.14 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/sl/documents/product-information/mvabea-epar-product-information_sl.pdf)

Suomi (FI) (446.1 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/fi/documents/product-information/mvabea-epar-product-information_fi.pdf)

svenska (SV) (367.99 KB - PDF)

**First published:**

23/07/2020

**Last updated:**

14/05/2025

[View](/sv/documents/product-information/mvabea-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0023 26/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mvabea : EPAR - All authorised presentations

English (EN) (42.88 KB - PDF)

**First published:** 23/07/2020

[View](/en/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-487)

български (BG) (47.07 KB - PDF)

**First published:**

23/07/2020

[View](/bg/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_bg.pdf)

español (ES) (37.97 KB - PDF)

**First published:**

23/07/2020

[View](/es/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_es.pdf)

čeština (CS) (68.78 KB - PDF)

**First published:**

23/07/2020

[View](/cs/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (44.43 KB - PDF)

**First published:**

23/07/2020

[View](/da/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.46 KB - PDF)

**First published:**

23/07/2020

[View](/de/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (37.76 KB - PDF)

**First published:**

23/07/2020

[View](/et/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (46.43 KB - PDF)

**First published:**

23/07/2020

[View](/el/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_el.pdf)

français (FR) (42.89 KB - PDF)

**First published:**

23/07/2020

[View](/fr/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (44.84 KB - PDF)

**First published:**

23/07/2020

[View](/hr/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (39.89 KB - PDF)

**First published:**

23/07/2020

[View](/is/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_is.pdf)

italiano (IT) (49.28 KB - PDF)

**First published:**

23/07/2020

[View](/it/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (44.61 KB - PDF)

**First published:**

23/07/2020

[View](/lv/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.29 KB - PDF)

**First published:**

23/07/2020

[View](/lt/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (38.46 KB - PDF)

**First published:**

23/07/2020

[View](/hu/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (45.85 KB - PDF)

**First published:**

23/07/2020

[View](/mt/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (42.17 KB - PDF)

**First published:**

23/07/2020

[View](/nl/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (43.79 KB - PDF)

**First published:**

23/07/2020

[View](/no/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_no.pdf)

polski (PL) (40.79 KB - PDF)

**First published:**

23/07/2020

[View](/pl/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.49 KB - PDF)

**First published:**

23/07/2020

[View](/pt/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_pt.pdf)

română (RO) (41.96 KB - PDF)

**First published:**

23/07/2020

[View](/ro/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (39.36 KB - PDF)

**First published:**

23/07/2020

[View](/sk/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38.46 KB - PDF)

**First published:**

23/07/2020

[View](/sl/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (42.35 KB - PDF)

**First published:**

23/07/2020

[View](/fi/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (42.4 KB - PDF)

**First published:**

23/07/2020

[View](/sv/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mvabea Active substance recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP International non-proprietary name (INN) or common name Ebola vaccine (MVA-BN-Filo [recombinant]) Therapeutic area (MeSH) Hemorrhagic Fever, Ebola Anatomical therapeutic chemical (ATC) code J07BX

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Active immunization for prevention of disease caused by Ebola virus (Zaire Ebolavirus species) in individuals ? 1 year of age.

## Authorisation details

EMA product number EMEA/H/C/005343

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Janssen-Cilag International N.V.

Turnhoutseweg 30

Opinion adopted 28/05/2020 Marketing authorisation issued 01/07/2020 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mvabea : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (197.82 KB - PDF)

**First published:** 31/08/2021

**Last updated:** 07/04/2025

[View](/en/documents/procedural-steps-after/mvabea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Mvabea-H-C-5343-P46-008 : EPAR - Assessment report

Adopted

Reference Number: EMA/529495/2023

English (EN) (567.71 KB - PDF)

**First published:** 24/11/2023

[View](/en/documents/variation-report/mvabea-h-c-5343-p46-008-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Mvabea : EPAR - Public assessment report

Adopted

Reference Number: EMA/323668/2020

English (EN) (2.23 MB - PDF)

**First published:** 23/07/2020

**Last updated:** 24/11/2020

[View](/en/documents/assessment-report/mvabea-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mvabea

Adopted

Reference Number: EMA/CHMP/138136/2020

English (EN) (140.57 KB - PDF)

**First published:** 29/05/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mvabea_en.pdf)

#### News on Mvabea

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020) 29/05/2020

[New vaccine for prevention of Ebola virus disease recommended for approval in the European Union](/en/news/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union) 29/05/2020

#### More information on Mvabea

- [EMEA-002308-PIP01-17-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002308-pip01-17-m02)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 14/05/2025

## Share this page

[Back to top](#main-content)